Orrick Advises Ipsen on Acquisition of Kartos Therapeutics for up to $1.75 Billion

Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Kartos Therapeutics for up to $1.75 billion. Under the terms of the agreement and plan of merger, Ipsen, through a fully-owned subsidiary, will pay $450 million upfront at closing. Kartos Therapeutics shareholders are also eligible to receive additional milestone payments of up to $1.3 billion including a significant regulatory approval milestone and sales-based milestones.

Orrick is representing Ipsen.

THE COMPANIES

Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. The company's pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K.

Kartos Therapeutics is a clinical-stage biopharmaceutical company developing navtemadlin, a potential best-in-class MDM2 inhibitor. The company is focused on harnessing the therapeutic potential of p53 pathway activation to develop innovative treatments for patients with myeloproliferative neoplasms, including myelofibrosis, where substantial unmet medical need persists.

THE IMPACT

The acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen's growing Oncology portfolio.

This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer," said David Loew, CEO, Ipsen. "We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response to current standard of care, addressing a critical care gap and offering the potential for a new therapeutic option as early as 2028.

THE TEAM

Tony Chan led the team that advised Ipsen, with invaluable support from Ramy Shweiky, Mary Ann Gallucci, Esther Kang, Charlie Kauffman, Jason Flaherty, Karen Cannon, Eric Wall, David Sharrow, Esteban De La Torre, Georgia Ravitz, Craig Falls, Danielle Mangogna, Jeanine McGuinness, Shruthi Maganti, Christina Bouchot, Shannon Yavorsky, Shari Esfahani, Carly Owens, Peter Graham, Nicole Walsh and Robin Freedman.

LEARN MORE

• Ipsen news release
• Read More Orrick Client Results